マイクロRNAの世界市場 - 市場規模、シェア、成長分析：研究ツール別（サービス・製品）、最終用途別（バイオテクノロジー企業、製薬会社、学術・政府研究機関） - 業界予測（2023年～2030年）

世界のマイクロRNAの市場規模は、2021年に10億159万米ドル、2022年に11億7,386万米ドルとなりました。同市場は、予測期間中（2023年～2030年）に17.2%のCAGRで拡大し、2030年には41億7,866万米ドルに成長する見通しです。

近年、世界のマイクロRNA市場は、分子生物学、ゲノミクス、バイオインフォマティクスの進歩に後押しされ、顕著な拡大を遂げています。低分子ノンコーディングRNAであるマイクロRNA（miRNA）は、遺伝子発現の制御において極めて重要な役割を担っており、様々な疾患の貴重なバイオマーカーとして、また治療介入の潜在的な標的として注目されています。疾患経路におけるmiRNAの関与と診断・治療ツールとしての可能性に対する理解が深まりつつあることが、この市場成長の原動力となっています。加えて、がん、心血管障害、神経疾患などの慢性疾患の有病率が上昇していることも、この動向を後押ししています。マイクロRNAは疾患の診断、予後、治療において大きな可能性を示しており、この分野での研究努力と投資の高まりに拍車をかけています。さらに、次世代シークエンシングやマイクロアレイプラットフォームなど、miRNAのプロファイリングや検出のための先端技術の出現により、miRNAバイオマーカーの分析や同定が効率化され、市場の拡大をさらに後押ししています。とはいえ、世界のマイクロRNA市場は、持続的な成長を確保するために対処しなければならないいくつかの障害に直面しています。極めて重要な課題は、miRNAに基づく治療薬や診断薬を取り巻く複雑な規制の枠組みにあります。miRNAに基づく製品の承認プロセスには、厳格な規制上の前提条件と臨床試験が必要であり、時間とコストがかかります。miRNAに基づく介入の安全性、有効性、特異性を保証することは、研究者や業界の利害関係者にとって大きなハードルとなります。もう一つの障害は、miRNAの機能と生物学的システム内での複雑な相互作用についての理解が限られていることです。

次世代シーケンシングやマイクロアレイプラットフォームのような技術革新に代表されるゲノミクスと分子生物学の急速な進歩は、ハイスループットなマイクロRNA解析の時代を到来させました。これらの最先端技術は、マイクロRNAの発見と詳細なプロファイリングに不可欠な機器を研究者に提供し、研究活動の活発化を促し、市場の拡大に拍車をかけています。

がん、心血管疾患、神経疾患などの慢性疾患の有病率は世界的に上昇傾向にあります。マイクロRNAは、これらの疾患を早期に特定し評価するための指標として大きな可能性を示しています。精密で非侵入的な診断機器への要求が高まっていることが、マイクロRNAの研究と進歩への関心を促進しています。

当レポートは、世界のマイクロRNA市場について調査し、市場の概要とともに、研究ツール別、最終用途別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

親市場分析

市場規模

• 市場力学
• 促進要因
• 機会
• 抑制要因
• 課題

主要な市場の洞察

• 技術分析
• 価格分析
• サプライチェーン分析
• バリューチェーン分析
• 市場のエコシステム
• IP分析
• 動向分析
• スタートアップ分析
• 原材料分析
• イノベーションマトリックス
• パイプライン製品分析
• マクロ経済指標
• 主な投資分析
• 主な成功要因
• 競合の程度

市場力学と見通し

• 市場力学
• 促進要因
• 機会
• 抑制要因
• 課題
• 規制状況
• ポーターの分析

世界のマイクロRNA市場、研究ツール別

• 市場概要
• サービス、製品

世界のマイクロRNA市場、最終用途別

• 市場概要
• バイオテクノロジー企業、製薬会社
• 学術・政府研究機関
• その他

世界のマイクロRNA市場、地域別

• 市場概要
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

競合情勢

• 主要企業プロファイル
  • Qiagen
  • Thermo Fisher Scientific Inc
  • Agilent Technologies, Inc.
  • Illumina, Inc.
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd.
  • Bio-Rad Laboratories, Inc.
  • PerkinElmer, Inc.
  • System Biosciences LLC
  • New England Biolabs, Inc
  • NanoString Technologies, Inc.
  • Exiqon A/S
  • Takara Bio Inc.
  • GenScript Biotech Corporation
  • Eurofins Scientific SE
  • Novartis AG
  • Bio-Techne Corporation
  • Agios Pharmaceuticals, Inc.
  • Abcam plc
  • Promega Corporation

Global MicroRNA Market size was valued at USD 1001.59 Million in 2021 and is poised to grow from USD 1173.86 Million in 2022 to USD 4178.66 Million by 2030, at a CAGR of 17.2% during the forecast period (2023-2030).

In recent years, the global microRNA market has experienced notable expansion, propelled by advancements in molecular biology, genomics, and bioinformatics. MicroRNAs (miRNAs), small non-coding RNA molecules, play a pivotal role in regulating gene expression, rendering them valuable biomarkers for various diseases and potential targets for therapeutic interventions. The growing comprehension of miRNA's involvement in disease pathways and their potential as diagnostic and therapeutic tools has been a driving force behind this market growth. Additionally, the escalating prevalence of chronic diseases like cancer, cardiovascular disorders, and neurological conditions has contributed to this trend. MicroRNAs have exhibited significant promise in disease diagnosis, prognosis, and treatment, spurring heightened research efforts and investments in the field. Moreover, the emergence of advanced technologies for miRNA profiling and detection, such as next-generation sequencing and microarray platforms, has streamlined the analysis and identification of miRNA biomarkers, further propelling market expansion. Nevertheless, the global microRNA market confronts several obstacles that must be addressed to ensure sustained growth. A pivotal challenge lies in the intricate regulatory framework surrounding miRNA-based therapeutics and diagnostics. The approval process for products based on miRNAs entails rigorous regulatory prerequisites and clinical trials, which can be both time-intensive and costly. Guaranteeing the safety, effectiveness, and specificity of miRNA-based interventions presents a significant hurdle for researchers and industry stakeholders. Another obstacle pertains to the limited understanding of miRNA functions and their intricate interactions within biological systems.

Top-down and bottom-up approaches were used to estimate and validate the size of the global microRNA market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report

Global MicroRNA Market is segmented on the basis of research tool, end-user, and region. By research tool, the market is segmented into services and products. By end use, the market is segmented into biotechnology and pharmaceutical companies, academic and government research institutes, and others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers:

Advancements in Genomics and Molecular Biology Technologies

The rapid progress in genomics and molecular biology, exemplified by innovations like next-generation sequencing and microarray platforms, has ushered in an era of high-throughput microRNA analysis. These cutting-edge technologies furnish researchers with indispensable instruments for the discovery and in-depth profiling of microRNAs, catalyzing heightened research endeavors and fueling market expansion.

Rising Prevalence of Chronic Diseases

The prevalence of chronic diseases worldwide, such as cancer, cardiovascular conditions, and neurological disorders, is on the rise. MicroRNAs have demonstrated significant promise as indicators for the early identification and assessment of these ailments. The growing requirement for precise and non-intrusive diagnostic instruments has fueled the interest in microRNA research and advancement.

Restraints:

Limited Understanding of microRNA Functions

Despite extensive research on microRNAs, many aspects of their precise functions and mechanisms of action remain elusive. The incomplete comprehension of microRNA biology presents obstacles in the identification of dependable and specific biomarkers, as well as the development of successful therapeutic interventions.

Technical and Analytical Challenges

MicroRNA research grapples with technical and analytical hurdles, encompassing precise quantification, sample variance, and the establishment of standardized analysis techniques. These impediments have the potential to undermine the consistency and trustworthiness of microRNA research findings, which, in turn, may impede market expansion.

Market Trends:

The synergy between Industry and Academia in MicroRNA Research: The convergence of biotechnology and pharmaceutical firms, academic research establishments, and governmental bodies is becoming increasingly prevalent in microRNA research. These collaborations harness the collective expertise, resources, and knowledge of diverse stakeholders to expedite the development and commercialization of microRNA-based products and solutions.

Increasing Utilization of MicroRNAs in Disease Biomarker Investigation: MicroRNAs exhibit considerable promise as biomarkers for various diseases, primarily owing to their stable presence in various biological fluids. Research endeavors are concentrated on the identification of distinct microRNA patterns linked to diseases, facilitating early detection, precise diagnosis, and prognostication. The growing adoption of microRNAs as disease biomarkers is propelling market expansion.

Table of Contents

• Executive Summary
  • Market Overview
  • Wheel of Fortune
• Research Methodology
  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations
• Parent Market Analysis
  • Market Overview
  • Market Size
  • Market Dynamics
• Drivers
• Opportunities
• Restraints
• Challenges
• Key Market Insights
  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition
• Market Dynamics & Outlook
  • Market Dynamics
• Drivers
• Opportunities
• Restraints
• Challenges
  • Regulatory Landscape
  • Porters Analysis
• Competitive rivalry
• Threat of Substitute Products
• Bargaining Power of Buyers
• Threat of New Entrants
• Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
• Political Impact
• Economic Impact
• Social Impact
• Technical Impact
• Environmental Impact
• Legal Impact
• Global MicroRNA Market by Research Tool
  • Market Overview
  • Service and product
• Global MicroRNA Market by End-use
  • Market Overview
  • Biotechnology and pharmaceutical companies
  • academic and government research institutes
  • and others
• Global MicroRNA Market Size by Region
  • Market Overview
  • North America
• USA
• Canada
  • Europe
• Germany
• Spain
• France
• UK
• Rest of Europe
  • Asia Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
  • Latin America
• Brazil
• Rest of Latin America
  • Middle East & Africa (MEA)
• GCC Countries
• South Africa
• Rest of MEA
• Competitive Landscape
  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
• By Development
• By Company
• By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021
• Key Company Profiles
  • Qiagen N.V. - Netherlands
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Thermo Fisher Scientific Inc. - US
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Agilent Technologies, Inc. - US
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Illumina, Inc. - US
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Merck KGaA - Germany
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • F. Hoffmann-La Roche Ltd. - Switzerland
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Bio-Rad Laboratories, Inc. - US
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • PerkinElmer, Inc. - US
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • System Biosciences LLC - US
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • New England Biolabs, Inc. - US
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • NanoString Technologies, Inc. - US
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Exiqon A/S - Denmark
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Takara Bio Inc. - Japan
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • GenScript Biotech Corporation - US
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Eurofins Scientific SE - Luxembourg
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Novartis AG - Switzerland
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Bio-Techne Corporation - US
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Agios Pharmaceuticals, Inc. - US
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Abcam plc - United Kingdom
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Promega Corporation - US
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments